MAIA Biotechnology reports patient enrollment milestones in Phase 2 and Phase 3 NSCLC trials
MAIA Biotechnology said it achieved patient enrollment milestones in its ongoing Phase 2 and pivotal Phase 3 clinical trials in non-small cell lung cancer.
MAIA Biotechnology said it achieved patient enrollment milestones in its ongoing Phase 2 and pivotal Phase 3 clinical trials in non-small cell lung cancer.